It gently breaks apart the blockage, making the plaque particles small enough to pass safely through the bloodstream
Liraglutide, a once daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
Importantly, GLP-1 appears to attenuate reward-driven food consumption by modulating dopaminergic signaling in the mesolimbic system, potentially reducing preference for high-fat, energy-dense foods [36]
Small pinhead bubbles are generally not a concern for subcutaneous injections
For more information, please visit the FDAs website How Is GLP-1 Administered
Clinical perspectives of new insights and tools to minimise the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy